The global Plasmid DNA market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Plasmid DNA is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Plasmid DNA is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Plasmid DNA in Viral Vector is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Plasmid DNA include Charles River Laboratories, Pfizer, Thermo Fisher, NEB, Aldevron, TriLink Bio Technologies, QIAGEN, AcuraBio and Takara Bio Inc., etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Plasmid DNA, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Plasmid DNA.
The Plasmid DNA market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Plasmid DNA market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Plasmid DNA companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Charles River Laboratories
Pfizer
Thermo Fisher
NEB
Aldevron
TriLink Bio Technologies
QIAGEN
AcuraBio
Takara Bio Inc.
Promega
PlasmidFactory GmbH
Creative Biogene
Eurogentec
Anemocyte
VGXI
GenScript
ABOGEN
WuXi Biologics
PackGene
Novoprotein
Segment by Type
Research Grade
GMP Grade
Other
Segment by Application
Viral Vector
mRNA Vaccine
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Plasmid DNA companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Plasmid DNA 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Research Grade
1.2.3 GMP Grade
1.2.4 Other
1.3 麻豆原创 by Application
1.3.1 Global Plasmid DNA 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Viral Vector
1.3.3 mRNA Vaccine
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Plasmid DNA 麻豆原创 Perspective (2018-2029)
2.2 Plasmid DNA Growth Trends by Region
2.2.1 Global Plasmid DNA 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Plasmid DNA Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Plasmid DNA Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Plasmid DNA 麻豆原创 Dynamics
2.3.1 Plasmid DNA Industry Trends
2.3.2 Plasmid DNA 麻豆原创 Drivers
2.3.3 Plasmid DNA 麻豆原创 Challenges
2.3.4 Plasmid DNA 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Plasmid DNA Players by Revenue
3.1.1 Global Top Plasmid DNA Players by Revenue (2018-2023)
3.1.2 Global Plasmid DNA Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Plasmid DNA 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Plasmid DNA Revenue
3.4 Global Plasmid DNA 麻豆原创 Concentration Ratio
3.4.1 Global Plasmid DNA 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Plasmid DNA Revenue in 2022
3.5 Plasmid DNA Key Players Head office and Area Served
3.6 Key Players Plasmid DNA Product Solution and Service
3.7 Date of Enter into Plasmid DNA 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Plasmid DNA Breakdown Data by Type
4.1 Global Plasmid DNA Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Plasmid DNA Forecasted 麻豆原创 Size by Type (2024-2029)
5 Plasmid DNA Breakdown Data by Application
5.1 Global Plasmid DNA Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Plasmid DNA Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Plasmid DNA 麻豆原创 Size (2018-2029)
6.2 North America Plasmid DNA 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Plasmid DNA 麻豆原创 Size by Country (2018-2023)
6.4 North America Plasmid DNA 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Plasmid DNA 麻豆原创 Size (2018-2029)
7.2 Europe Plasmid DNA 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Plasmid DNA 麻豆原创 Size by Country (2018-2023)
7.4 Europe Plasmid DNA 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Plasmid DNA 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Plasmid DNA 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Plasmid DNA 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Plasmid DNA 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Plasmid DNA 麻豆原创 Size (2018-2029)
9.2 Latin America Plasmid DNA 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Plasmid DNA 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Plasmid DNA 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Plasmid DNA 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Plasmid DNA 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Plasmid DNA 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Plasmid DNA 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Charles River Laboratories
11.1.1 Charles River Laboratories Company Detail
11.1.2 Charles River Laboratories Business Overview
11.1.3 Charles River Laboratories Plasmid DNA Introduction
11.1.4 Charles River Laboratories Revenue in Plasmid DNA Business (2018-2023)
11.1.5 Charles River Laboratories Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Plasmid DNA Introduction
11.2.4 Pfizer Revenue in Plasmid DNA Business (2018-2023)
11.2.5 Pfizer Recent Development
11.3 Thermo Fisher
11.3.1 Thermo Fisher Company Detail
11.3.2 Thermo Fisher Business Overview
11.3.3 Thermo Fisher Plasmid DNA Introduction
11.3.4 Thermo Fisher Revenue in Plasmid DNA Business (2018-2023)
11.3.5 Thermo Fisher Recent Development
11.4 NEB
11.4.1 NEB Company Detail
11.4.2 NEB Business Overview
11.4.3 NEB Plasmid DNA Introduction
11.4.4 NEB Revenue in Plasmid DNA Business (2018-2023)
11.4.5 NEB Recent Development
11.5 Aldevron
11.5.1 Aldevron Company Detail
11.5.2 Aldevron Business Overview
11.5.3 Aldevron Plasmid DNA Introduction
11.5.4 Aldevron Revenue in Plasmid DNA Business (2018-2023)
11.5.5 Aldevron Recent Development
11.6 TriLink Bio Technologies
11.6.1 TriLink Bio Technologies Company Detail
11.6.2 TriLink Bio Technologies Business Overview
11.6.3 TriLink Bio Technologies Plasmid DNA Introduction
11.6.4 TriLink Bio Technologies Revenue in Plasmid DNA Business (2018-2023)
11.6.5 TriLink Bio Technologies Recent Development
11.7 QIAGEN
11.7.1 QIAGEN Company Detail
11.7.2 QIAGEN Business Overview
11.7.3 QIAGEN Plasmid DNA Introduction
11.7.4 QIAGEN Revenue in Plasmid DNA Business (2018-2023)
11.7.5 QIAGEN Recent Development
11.8 AcuraBio
11.8.1 AcuraBio Company Detail
11.8.2 AcuraBio Business Overview
11.8.3 AcuraBio Plasmid DNA Introduction
11.8.4 AcuraBio Revenue in Plasmid DNA Business (2018-2023)
11.8.5 AcuraBio Recent Development
11.9 Takara Bio Inc.
11.9.1 Takara Bio Inc. Company Detail
11.9.2 Takara Bio Inc. Business Overview
11.9.3 Takara Bio Inc. Plasmid DNA Introduction
11.9.4 Takara Bio Inc. Revenue in Plasmid DNA Business (2018-2023)
11.9.5 Takara Bio Inc. Recent Development
11.10 Promega
11.10.1 Promega Company Detail
11.10.2 Promega Business Overview
11.10.3 Promega Plasmid DNA Introduction
11.10.4 Promega Revenue in Plasmid DNA Business (2018-2023)
11.10.5 Promega Recent Development
11.11 PlasmidFactory GmbH
11.11.1 PlasmidFactory GmbH Company Detail
11.11.2 PlasmidFactory GmbH Business Overview
11.11.3 PlasmidFactory GmbH Plasmid DNA Introduction
11.11.4 PlasmidFactory GmbH Revenue in Plasmid DNA Business (2018-2023)
11.11.5 PlasmidFactory GmbH Recent Development
11.12 Creative Biogene
11.12.1 Creative Biogene Company Detail
11.12.2 Creative Biogene Business Overview
11.12.3 Creative Biogene Plasmid DNA Introduction
11.12.4 Creative Biogene Revenue in Plasmid DNA Business (2018-2023)
11.12.5 Creative Biogene Recent Development
11.13 Eurogentec
11.13.1 Eurogentec Company Detail
11.13.2 Eurogentec Business Overview
11.13.3 Eurogentec Plasmid DNA Introduction
11.13.4 Eurogentec Revenue in Plasmid DNA Business (2018-2023)
11.13.5 Eurogentec Recent Development
11.14 Anemocyte
11.14.1 Anemocyte Company Detail
11.14.2 Anemocyte Business Overview
11.14.3 Anemocyte Plasmid DNA Introduction
11.14.4 Anemocyte Revenue in Plasmid DNA Business (2018-2023)
11.14.5 Anemocyte Recent Development
11.15 VGXI
11.15.1 VGXI Company Detail
11.15.2 VGXI Business Overview
11.15.3 VGXI Plasmid DNA Introduction
11.15.4 VGXI Revenue in Plasmid DNA Business (2018-2023)
11.15.5 VGXI Recent Development
11.16 GenScript
11.16.1 GenScript Company Detail
11.16.2 GenScript Business Overview
11.16.3 GenScript Plasmid DNA Introduction
11.16.4 GenScript Revenue in Plasmid DNA Business (2018-2023)
11.16.5 GenScript Recent Development
11.17 ABOGEN
11.17.1 ABOGEN Company Detail
11.17.2 ABOGEN Business Overview
11.17.3 ABOGEN Plasmid DNA Introduction
11.17.4 ABOGEN Revenue in Plasmid DNA Business (2018-2023)
11.17.5 ABOGEN Recent Development
11.18 WuXi Biologics
11.18.1 WuXi Biologics Company Detail
11.18.2 WuXi Biologics Business Overview
11.18.3 WuXi Biologics Plasmid DNA Introduction
11.18.4 WuXi Biologics Revenue in Plasmid DNA Business (2018-2023)
11.18.5 WuXi Biologics Recent Development
11.19 PackGene
11.19.1 PackGene Company Detail
11.19.2 PackGene Business Overview
11.19.3 PackGene Plasmid DNA Introduction
11.19.4 PackGene Revenue in Plasmid DNA Business (2018-2023)
11.19.5 PackGene Recent Development
11.20 Novoprotein
11.20.1 Novoprotein Company Detail
11.20.2 Novoprotein Business Overview
11.20.3 Novoprotein Plasmid DNA Introduction
11.20.4 Novoprotein Revenue in Plasmid DNA Business (2018-2023)
11.20.5 Novoprotein Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Charles River Laboratories
Pfizer
Thermo Fisher
NEB
Aldevron
TriLink Bio Technologies
QIAGEN
AcuraBio
Takara Bio Inc.
Promega
PlasmidFactory GmbH
Creative Biogene
Eurogentec
Anemocyte
VGXI
GenScript
ABOGEN
WuXi Biologics
PackGene
Novoprotein
听
听
*If Applicable.
